Valuation, from the filing
| Public float | $13.64M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-04-30 |
|---|---|---|
| Float per share | $0.60 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / revenue | 1.5× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 1.1× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-04-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-10-31 — the year that filing covered.
Valuation over time
10.4× earnings today, against a median of 6.9× across 5 years on record. Above its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2023-04-30 | $13.64M | 10.4× | |
| 2022-04-30 | $12.34M | 12.3× | |
| 2020-04-30 | $11.29M | 5.5× | |
| 2019-04-30 | $14.35M | 6.9× | |
| 2018-04-30 | $8.00M | 6.3× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
How this compares in its industry
Percentile among the Services-Management Consulting Services filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| SBC / revenue | 0.4% | 0th | |
| Current ratio | 7.70x | 98th | |
| CapEx / revenue | 0.1% | 16th | |
| FCF margin | -2.5% | 32th | |
| Revenue YoY growth | -5.3% | 33th | |
| Gross margin | 32.3% | 37th | |
| Net margin | -1.1% | 44th | |
| Operating margin | -7.1% | 47th |
Pharma-Bio Serv, Inc. (PBSV) reported revenue of $9.48M and net income of $251.52K for the fiscal year ended 2026-07-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Pharma-Bio Serv, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Management Consulting Services.
Income
| Metric | 2026-07-31 |
|---|---|
| Revenue | $9.48M |
| Cost of revenue | $6.42M |
| Gross profit | $3.07M |
| Operating income | -$154.94K |
| Net income | $251.52K |
| Research & development | Unavailable |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $269.00K |
| Income tax expense | $17.47K |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $3.22M |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-07-31 |
|---|---|
| Cash & equivalents | Unavailable |
| Total assets | $11.44M |
| Current assets | $11.24M |
| Total liabilities | $994.74K |
| Current liabilities | $994.74K |
| Total equity incl. NCI | $10.44M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | Unavailable |
| Accounts receivable | $2.42M |
| Goodwill | Unavailable |
| Long-term debt | Unavailable |
| Accounts payable | Unavailable |
Cash flow
| Metric | 2026-07-31 |
|---|---|
| Operating cash flow | -$414.89K |
| Capital expenditures | $6.47K |
| Investing cash flow | -$303.36K |
| Financing cash flow | -$1.73M |
| Net change in cash | -$2.44M |
| Stock-based compensation | $30.26K |
| Common dividends paid | Unavailable |
| Common share repurchases | $11.59K |
| Depreciation & amortization | $57.94K |
Derived
| Metric | 2026-07-31 |
|---|---|
| Free cash flow | -$421.36K |
| Gross margin | 32.3% |
| Operating margin | -1.6% |
| FCF margin | -4.4% |
| SBC / revenue | 0.3% |
| Current ratio | 11.30x |
| Revenue YoY growth | 3.3% |
| Net margin | 2.7% |
| R&D / revenue | Unavailable |
| CapEx / revenue | 0.1% |
| Long-term debt / equity | Unavailable |
| Effective tax rate | 6.5% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PBSV in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.